NL-OMON56910尚未招募不适用
Characterizing the Tumor Immune Microenvironment of Head and Neck Squamous Cell Carcinoma - HNcol 2.0
Amsterdam UMC0 个研究点目标入组 1,600 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients are scheduled for panendoscopy or surgery for squamous cell
- •carcinoma of the oral cavity, oropharynx, hypopharynx, larynx or cervical part
- •of oesophagus.
- •2. Patients must have sufficient knowledge of the Dutch language to understand
- •the meaning of the study as described in the patient information.
- •3. Patients must have the mental capacity to understand the meaning of the
- •study as described in the patient information.
- •4. Patients must give written informed consent.
- •5. Age of the patients should be >18. An upper limit of age will not be
- •applied. Elderly patients who are fit enough to undergo surgery in the head and
- •neck area are not likely to encounter negative effects of the extra procedures
- •that will be applied as part of the study.
排除标准
- •Too limited size of the carcinoma according to the treating physician.
研究者
相似试验
招募中
不适用
Analysis of tumor immune microenvironments and host immune responses in cancer patientsmalignancyJPRN-UMIN000016678Kawasaki Medical School1,000
已完成
不适用
Comprehensive analysis of tumor immune microenvironment in small cell lung cancerSmall cell lung cancer (SCLC)JPRN-UMIN000041056Kindai university, Faculty of Medicine, Department of Medical Oncology340
招募中
不适用
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer PatientsLung CancerEsophageal CancerNCT05789498Zhao Jun60
进行中（未招募）
1 期
Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients.non-small cell lung cancerEUCTR2020-005562-34-FRInstitut Bergonié80
招募中
不适用
Interaction Between Host, Microenvironment and Immunity on Gastrointestinal NeoplasmsGastrointestinal NeoplasmsNCT04363983Assistance Publique - Hôpitaux de Paris6,300